Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-02-14 4:45 pm Purchase | 13G | Concert Pharmaceuticals, Inc. CNCE | RA CAPITAL MANAGEMENT L.P. | 5,199,746 9.99% | 1,689,643 (+48.14%) | View |
| 2023-02-14 2:35 pm Sale | 13G | Concert Pharmaceuticals, Inc. CNCE | PERCEPTIVE ADVISORS LLC | 1,800,000 3.6% | -350,641 (-16.30%) | View |
| 2023-02-13 6:02 pm Purchase | 13G | Concert Pharmaceuticals, Inc. CNCE | BIOTECHNOLOGY VALUE FUND L P | 4,917,774 9.99% | 1,321,017 (+36.73%) | View |
| 2023-02-13 09:25 am Unchanged | 13G | Concert Pharmaceuticals, Inc. CNCE | Kynam Capital Management LP | 4,420,349 9.2% | 0 (Unchanged) | View |
| 2023-02-10 3:51 pm Purchase | 13G | Concert Pharmaceuticals, Inc. CNCE | Kynam Capital Management LP | 4,420,349 9.2% | 4,420,349 (New Position) | View |
| 2022-02-14 4:11 pm Purchase | 13G | Concert Pharmaceuticals, Inc. CNCE | RA CAPITAL MANAGEMENT L.P. | 3,510,103 9.99% | 1,686,583 (+92.49%) | View |
| 2022-02-14 3:46 pm Unchanged | 13G | Concert Pharmaceuticals, Inc. CNCE | PERCEPTIVE ADVISORS LLC | 2,150,641 6.2% | 0 (Unchanged) | View |
| 2022-01-13 10:20 am Sale | 13G | Concert Pharmaceuticals, Inc. CNCE | BANK OF AMERICA CORP BAC | 1,007,258 2.9% | -870,960 (-46.37%) | View |
| 2021-11-15 4:58 pm Purchase | 13G | Concert Pharmaceuticals, Inc. CNCE | BIOTECHNOLOGY VALUE FUND L P | 3,596,757 9.99% | 3,596,757 (New Position) | View |
| 2021-07-12 08:29 am Sale | 13G | Concert Pharmaceuticals, Inc. CNCE | BlackRock Inc. BLK | 670,035 2.1% | -1,534,474 (-69.61%) | View |
| 2021-02-16 4:39 pm Purchase | 13G | Concert Pharmaceuticals, Inc. CNCE | RA CAPITAL MANAGEMENT L.P. | 1,823,520 5.9% | 1,823,520 (New Position) | View |
| 2021-02-16 3:30 pm Unchanged | 13G | Concert Pharmaceuticals, Inc. CNCE | PERCEPTIVE ADVISORS LLC | 2,150,641 7% | 0 (Unchanged) | View |
| 2021-02-12 4:38 pm Sale | 13G | Concert Pharmaceuticals, Inc. CNCE | DIMENSIONAL FUND ADVISORS LP | 1,079,170 3.5% | -129,831 (-10.74%) | View |
| 2021-02-09 4:41 pm Sale | 13G | Concert Pharmaceuticals, Inc. CNCE | INGALLS & SNYDER LLC | 1,396,003 4.55% | -68,709 (-4.69%) | View |
| 2021-02-08 5:06 pm Purchase | 13G | Concert Pharmaceuticals, Inc. CNCE | BANK OF AMERICA CORP BAC | 1,878,218 6.1% | 67,012 (+3.70%) | View |
| 2021-02-02 2:56 pm Purchase | 13G | Concert Pharmaceuticals, Inc. CNCE | BlackRock Inc. BLK | 2,204,509 7.2% | 735,550 (+50.07%) | View |
| 2020-02-14 5:01 pm Unchanged | 13G | Concert Pharmaceuticals, Inc. CNCE | GSK plc | 1,179,941 4.1% | 0 (Unchanged) | View |
| 2020-02-14 4:28 pm Purchase | 13G | Concert Pharmaceuticals, Inc. CNCE | PERCEPTIVE ADVISORS LLC | 2,150,641 9% | 276,862 (+14.78%) | View |
| 2020-02-14 3:13 pm Sale | 13G | Concert Pharmaceuticals, Inc. CNCE | BIOTECHNOLOGY VALUE FUND L P | 0 0% | -1,408,187 (Position Closed) | View |
| 2020-02-14 1:30 pm Sale | 13G | Concert Pharmaceuticals, Inc. CNCE | RTW INVESTMENTS LP | 0 0% | -1,811,662 (Position Closed) | View |